Stalevo

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2004-2013
02420042013

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
OBJECTIVE To assess the efficacy and tolerability of the three component drug stalevo in the treatment of patients with Parkinson… (More)
Is this relevant?
Review
2013
Review
2013
The results of the large-scale study STRIDE-PD of patients with Parkinson's disease (PD) are presented. The aim of the study was… (More)
Is this relevant?
2012
2012
Levodopa remains a 'gold standard' for the treatment of patients with Parkinson's disease (PD), but its chronic use is… (More)
Is this relevant?
2011
2011
All patients with Parkinson's disease (PD) with motor fluctuations due to long-term levodopa therapy have at least one non-motor… (More)
Is this relevant?
2011
2011
Nocturnal symptoms are integral part of the general clinical picture of Parkinson's disease (PD). They are subdivided into non… (More)
Is this relevant?
2009
2009
The triple combination of levodopa, DDCI and entacapone (Stalevo) is used to treat motor complication in patients with Parkinson… (More)
Is this relevant?
2008
2008
The addition of entacapone to levodopa-carbidopa (LC) or the switch from LC to a tablet containing levodopa-carbidopa-entacapone… (More)
Is this relevant?
2007
2007
Despite significant symptomatic effect of levodopa, in most patients the stable 24 hour's effect changed for alterations of… (More)
Is this relevant?
2006
2006
Based on literature data on the usage of Dopa medications in the treatment of Parkinson's disease (PD), a characteristic of a new… (More)
Is this relevant?
2005
2005
The aim of this study was to evaluate the efficacy of the new optimised levodopa, Stalevo (levodopa, carbidopa and entacapone) in… (More)
Is this relevant?